(Q34033218)

English

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

rheumatoid arthritis

1 reference

based on heuristic

inferred from title

2

object named as

Josef S Smolen

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

object named as

Daniel Aletaha

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

1 December 2011

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

63

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

3702-3711

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Osteoclasts are essential for TNF-alpha-mediated joint destruction

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Patients with rheumatoid arthritis in clinical care

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Early rheumatoid arthritis: time to aim for remission?

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

New therapies for treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Superiority of SDAI over DAS-28 in assessment of remission in rheumatoid arthritis patients using power Doppler ultrasonography as a gold standard.

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group.

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with c

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Measurement of patient outcome in arthritis

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D).

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Does clinical remission lead to normalization of EQ-5D in patients with rheumatoid arthritis and is selection of remission criteria important?

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

The importance of reporting disease activity states in rheumatoid arthritis clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes

1 reference

https://api.crossref.org/works/10.1002%2FART.30634

21 January 2018

Identifiers

10.1002/ART.30634

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34033218&oldid=1538215157"